Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report
BackgroundFor patients with metastatic upper tract urothelial carcinoma (UTUC), the preferred first-line treatment is platinum-based chemotherapy. Immunotherapy can be considered a subsequent treatment if the chemotherapy is ineffective or the disease progresses. However, how should treatment be adm...
Shranjeno v:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2024-09-01
|
| Serija: | Frontiers in Oncology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1419882/full |
| Oznake: |
Brez oznak, prvi označite!
|